Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX vs FOLFOX4 in Advanced Hepatocellular Carcinoma
NCT02534337Phase 3Withdrawn
- Sponsor
- Guangxi Medical University
- Start
- Sep 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Guangxi Medical University. Primary endpoint: Progression-Free Survival at 3 months. Planned start Sep 2015; status: withdrawn.
02
Drugs
gemcitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02534337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534337.